A recent influential study conducted in ≈10 000 patients with type 2 diabetes mellitus demonstrated significant reduction in frequency of adverse cardiovascular events and death from cardiovascular causes by treatment with GLP-1 analogue liraglutide.3 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.